Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Status:
Completed
Trial end date:
2014-07-28
Target enrollment:
Participant gender:
Summary
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of
Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor
or tamoxifen.